Defining severe obstructive lung disease in the biologic era: an endotype-based approach

Richard J. Martin1, Elisabeth H. Bel2, Ian D. Pavord3, David Price4,5 and Helen K. Reddel6

Affiliations: 1National Jewish Health and the University of Colorado, Denver, CO, USA. 2Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. 3Respiratory Medicine Unit and NIHR Oxford Respiratory BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK. 4Observational and Pragmatic Research Institute, Singapore. 5Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK. 6Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia.

Correspondence: Richard J. Martin, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA. E-mail: MartinR@NJHealth.org

@ERSpublications

A new definition of severe obstructive lung disease is needed for the biologic era. Investigators, companies and regulators must collaborate in a phenotype- and endotype-based approach to improve access to biologics for patients most likely to benefit. http://bit.ly/2Zuiakg


This single-page version can be shared freely online.

ABSTRACT Severe obstructive lung disease, which encompasses asthma, chronic obstructive pulmonary disease (COPD) or features of both, remains a considerable global health problem and burden on healthcare resources. However, the clinical definitions of severe asthma and COPD do not reflect the heterogeneity within these diagnoses or the potential for overlap between them, which may lead to inappropriate treatment decisions. Furthermore, most studies exclude patients with diagnoses of both asthma and COPD. Clinical definitions can influence clinical trial design and are both influenced by, and influence, regulatory indications and treatment recommendations. Therefore, to ensure its relevance in the era of targeted biologic therapies, the definition of severe obstructive lung disease must be updated so that it includes all patients who could benefit from novel treatments and for whom associated costs are justified. Here, we review evolving clinical definitions of severe obstructive lung disease and evaluate how these have influenced trial design by summarising eligibility criteria and primary outcomes of phase III randomised controlled trials of biologic therapies. Based on our findings, we discuss the advantages of a phenotype- and endotype-based approach to select appropriate populations for future trials that may influence regulatory approvals and clinical practice, allowing targeted biologic therapies to benefit a greater proportion and range of patients. This calls for co-ordinated efforts between investigators, pharmaceutical developers and regulators to ensure biologic therapies reach their full potential in the management of severe obstructive lung disease.